Gladstone Institutional Advisory’s ALPS Medical Breakthroughs ETF SBIO Stock Holding History

Gladstone Institutional Advisory’s Portfolio SBIO Stock Details SBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-6,619	Closed	-$223K	–	721
2022 Q1	$223K	Buy	6,619 +1,695	+34%	+$58.7K	0.02%	634
2021 Q4	$208K	Buy	+4,924	New	+$219K	0.02%	556
2020 Q4	–	Sell	-12,001	Closed	-$494K	–	319
2020 Q3	$494K	Buy	+12,001	New	+$495K	0.12%	144
2020 Q1	–	Sell	-5,116	Closed	-$216K	–	311
2019 Q4	$216K	Sell	5,116 -1,329	-21%	-$49.3K	0.05%	249
2019 Q3	$203K	Sell	6,445 -333	-5%	-$11.7K	0.05%	266
2019 Q2	$245K	Buy	6,778 +1,076	+19%	+$37.1K	0.07%	225
2019 Q1	$206K	Buy	+5,702	New	+$190K	0.08%	203

Other funds holding SBIO

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

NAM

NTV Asset Management Charleston, West Virginia $910M AUM 27.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SFS

Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return

ASB Consultores Aventura, Florida $30.1M AUM 22.96% 1-Year Est. Return

Gladstone Institutional Advisory's SBIO Position: Q2 2022 in Review

Gladstone Institutional Advisory sold out of ALPS Medical Breakthroughs ETF (SBIO) in Q2 2022, closing a stake of 6,619 shares — an estimated $223K sold.

Gladstone Institutional Advisory first reported a position in SBIO in Q1 2019 and held it in 7 quarters. The position peaked at $494K in Q3 2020. 52 funds tracked by Wall St. Rank hold SBIO as of Q2 2022.

Gladstone Institutional Advisory reported no remaining ALPS Medical Breakthroughs ETF position as of Q2 2022 after selling out during the quarter.
Gladstone Institutional Advisory sold 6,619 ALPS Medical Breakthroughs ETF shares in Q2 2022, an estimated $223K.
Gladstone Institutional Advisory first reported a position in ALPS Medical Breakthroughs ETF in Q1 2019 and held it in 7 quarters.
Gladstone Institutional Advisory's ALPS Medical Breakthroughs ETF position peaked at $494K in Q3 2020.
52 funds tracked by Wall St. Rank held ALPS Medical Breakthroughs ETF as of Q2 2022.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2022, filed 15 Aug 2022.